-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LOXO-783 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LOXO-783 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-783 in Solid Tumor Drug Details: LOXO-783 (LOX-22783) is under development...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2023’, provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Rectal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Rectal Cancer - Drugs In Development, 2023’, provides an overview of the Rectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Salivary Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Salivary Gland Cancer - Drugs In Development, 2023’, provides an overview of the Salivary Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Medullary Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Medullary Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Medullary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Anaplastic Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Small Intestine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Small Intestine Cancer - Drugs In Development, 2023’, provides an overview of the Small Intestine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Small Intestine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...